CytomX Therapeutics, Inc. announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023, in San Diego, CA. "CX-2051 is designed to address the unmet needs of patients with EpCAM-expressing tumors, including colorectal cancer, where EpCAM expression is uniformly high. EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.605 USD | +0.94% | -4.19% | +3.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.23% | 108M | |
-2.56% | 103B | |
+1.78% | 95.28B | |
+1.46% | 22.15B | |
-15.30% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.43% | 16.05B | |
+4.14% | 13.68B | |
+35.55% | 12.17B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference